Drug pricing, FDA approvals, clinical trial data, and patient access are daily news topics. When a reporter calls, the story is already framed. Jess trains pharma and biotech leaders to walk into those conversations with clarity, confidence, and a message that lands.
No industry faces more sustained public and media scrutiny than pharmaceutical and biotech companies. Pricing controversies, breakthrough therapy announcements, clinical trial results, and safety recalls all carry enormous reputational stakes. Your executives must be able to speak fluently to journalists, investors, regulators, and patients — often with the same message, in the same interview.
No story attracts more aggressive questioning than drug costs. Your executives need answers that are honest, defensible, and don't create new headlines.
Approval day generates a wave of media interest. Spokespeople must communicate efficacy, safety, and access plans without over-promising or triggering regulatory concerns.
Journalists and investors scrutinize trial data for spin. Your scientific leaders must explain results in plain language while maintaining complete scientific integrity.
A safety update or voluntary recall is a pivotal moment. How you communicate in the first 24 hours determines how the story resolves — and how much trust survives.
Develop honest, clear language around drug economics that acknowledges cost concerns while explaining value and investment in research.
Turn complex clinical data, biomarker results, and trial endpoints into accessible narratives without losing accuracy.
Respond to safety signals, recalls, and adverse event coverage with a message that demonstrates accountability and patient focus.
Communicate pipeline milestones, approval timelines, and commercial strategy in ways that build long-term investor and analyst trust.
"This whole session was extremely helpful. I needed to work in all areas... I really can see my improvement on-screen. This will help me tremendously professionally."
Jess works with life sciences executives to ensure they can walk into any media situation — approval announcements, crisis moments, investor calls — with a message that holds up under pressure.
Get a Quick Quote